Table 4.
Treatment-related adverse events.
| AEs | Any grade | Grade 3/4 | ||||
|---|---|---|---|---|---|---|
| TO (N = 64) |
TA (N = 32) |
p | TO (N = 64) |
TA (N = 32) |
p | |
| Abdominal pain | 25 (39.1) | 12 (37.5) | 0.882 | 3 (4.7) | 1 (3.1) | <0.001 |
| Nausea | 22 (34.4) | 10 (31.3) | 0.759 | 0 (0) | 0 (0) | 1.000 |
| Diarrhea | 12 (18.8) | 7 (21.9) | 0.717 | 0 (0) | 1 (3.1) | 0.333 |
| Decreased appetite | 20 (31.3) | 15 (46.9) | 0.165 | 1 (1.6) | 2 (6.3) | 0.534 |
| Erythra | 0 (0) | 5 (15.6) | 0.006 | 0 (0) | 2 (6.3) | 0.109 |
| Fatigue | 6 (9.4) | 5 (15.6) | 0.571 | 0 (0) | 0 (0) | 1.000 |
| Hypoproteinemia | 12 (18.8) | 5 (15.6) | 0.656 | 2 (3.1) | 0 (0) | 0.551 |
| Elevated bilirubin | 10 (15.6) | 6 (18.8) | 0.699 | 1 (1.6) | 1 (3.1) | 1.000 |
| Elevated transaminases | 30 (46.9) | 18 (56.3) | 0.386 | 3 (4.7) | 2 (6.3) | 0.749 |
| Hypothyroidism | 0 (0) | 6 (18.8) | 0.001 | 0 (0) | 1 (3.1) | 0.333 |
| Decreased PLT | 9 (14.1) | 8 (25.0) | 0.186 | 0 (0) | 0 (0) | 1.000 |
| Hypertension | 3 (4.7) | 6 (18.8) | 0.063 | 0 (0) | 0 (0) | 1.000 |
| Hand–foot skin reaction | 0 (0) | 8 (25.0) | <0.001 | 0 (0) | 2 (6.3) | 0.109 |
| Dysphonia | 0 (2) | 2 (6.3) | 0.109 | 0 (0) | 0 (0) | 1.000 |
| Proteinuria | 2 (3.1) | 5 (15.6) | 0.071 | 0 (0) | 0 (0) | 1.000 |
| Bleeding (gingiva) | 1 (1.6) | 4 (12.5) | 0.081 | 0 (0) | 1 (3.1) | 0.333 |
| Joint pain | 0 (4) | 4 (12.5) | 0.012 | 0 (0) | 0 (0) | 1.000 |
TO, TACE only; TA, TACE combined with anlotinib; TACE, transarterial chemoembolization; AEs, adverse events; PLT, platelet count.